Recruiting
Pemafibrate for Symptomatic ICAS RCT
NCT07562178· Tokyo Women's Medical University· Source
Contact: Shoji Fujita
Recruiting
A Study of E6742 in Participants With Systemic Lupus Erythematosus
NCT07515014· Phase 2· Eisai Co., Ltd.· Source
Active, not recruiting
CoSMAP Trial: SP-EA vs MP-TA Robot-Assisted Radical Prostatectomy
NCT07666217· Intuitive Surgical· Source
Active, not recruiting
A Clinical Evaluation of AMJ-401
NCT07373353· Abbott Medical Devices· Source
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source
Contact: Clinical Trials
Recruiting
Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
NCT06611696· Phase 4· Chiba University· Source
Contact: Naotake Tsuboi, MD, PhD
Recruiting
Zephyr Valve Japan Post-Marketing Surveillance
NCT06332885· Pulmonx Corporation· Source
Contact: Risako Koshiyama
Active, not recruiting
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NCT06295692· Phase 3· Janssen Pharmaceutical K.K.· Source
Active, not recruiting
A Study of KK2269 in Adult Participants With Solid Tumors
NCT06266299· Phase 1· Kyowa Kirin Co., Ltd.· Source
Active, not recruiting
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
NCT05923866· Phase 2· Ono Pharmaceutical Co., Ltd.· Source
Active, not recruiting
Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome
NCT05914155· Phase 3· Shoichi Maruyama MD PhD· Source
Active, not recruiting
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
A Study of Lu AF82422 in Participants With Multiple System Atrophy
NCT05104476· Phase 2· H. Lundbeck A/S· Source
Active, not recruiting
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
NCT06540261· Phase 1· Ono Pharmaceutical Co., Ltd.· Source
Recruiting
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
NCT04803994· Phase 3· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source
Contact: Peter Galle, Prof. Dr.
Active, not recruiting
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
NCT04628494· Phase 3· Genmab· Source
Active, not recruiting
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
Atrasentan in Patients With IgA Nephropathy
NCT04573478· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
NCT04273945· Phase 3· Actelion· Source
Active, not recruiting
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
NCT04164901· Phase 3· Institut de Recherches Internationales Servier· Source
Active, not recruiting
A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer
NCT03807778· Phase 1· Takeda· Source
Active, not recruiting
Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices
NCT03366545· Biotronik SE & Co. KG· Source
Active, not recruiting
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
Japanese Idiopathic Interstitial Pneumonias Registry
NCT03041623· North East Japan Study Group· Source